Skip to main navigation Skip to search Skip to main content

ABLE 32: A Phase 3b, Randomized, Controlled Study of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC)

Project: Research

Project Details

StatusActive
Effective start/end date05/15/25 → 12/31/27

Funding

  • Ferring Pharmaceuticals A/S: $31,346.00